Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: The AnemOnHe study

European Journal of Cancer

Volumn 48, Issue 1, 2012, Pages 101-107

  Spielmann, Marc ^a   Luporsi, Elisabeth ^b   Ray Coquard, Isabelle ^c   De Botton, Stéphane ^a   Azria, David ^d   Lasocki, Sigismond ^e   Lafuma, Antoine ^f   Mahi, Lamine ^g   Deray, Gilbert ^h   Bugat, Roland ⁱ  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c UNIVERSITÉ DE LYON   (France)

^d CENTRE VAL D AURELLE   (France)

^e BICHAT HOSPITAL   (France)

^f CEMKA EVAL   (France)

^g Vifor (International) Inc   (Switzerland)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Anaemia; Chemotherapy induced anaemia; Erythropoiesis stimulating agents; Intravenous iron; Iron supplementation; Transfusion

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; DISEASE DURATION; FEMALE; FRANCE; HEMATOLOGIC MALIGNANCY; HUMAN; IRON DEFICIENCY; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; FEMALE; FRANCE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 83255187145     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.011     Document Type: Article

References (27)

1. J.U. Blohmer, J. Dunst, and L. Harrison Cancer-related anemia: biological findings, clinical implications and impact on quality of life Oncology 68 Suppl. 1 2005 12 21
2. H. Ludwig, S. Van Belle, and P. Barrett-Lee The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients Eur J Cancer 40 2004 2293 2306
3. G. Birgegard, P. Gascon, and H. Ludwig Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey Eur J Haematol 77 2006 378 386
4. J.L. Spivak, P. Gascon, and H. Ludwig Anemia management in oncology and hematology Oncologist 14 Suppl. 1 2009 43 56
5. Y. Beguin Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients Haematologica 87 2002 1209 1221
6. B. Young, and J. Zaritsky Hepcidin for clinicians Clin J Am Soc Nephrol 4 2009 1384 1387
7. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47:S11-45.
8. H. Ludwig, M. Aapro, and C. Bokemeyer Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study Eur J Cancer 45 2009 1603 1615
9. S.S. Shord, and S. Cuellar Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation J Am Pharm Assoc (2003) 48 2008 487 493
10. M. Auerbach, H. Ballard, and J.R. Trout Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial J Clin Oncol 22 2004 1301 1307
11. L. Bastit, A. Vandebroek, and S. Altintas Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia J Clin Oncol 26 2008 1611 1618
12. M. Hedenus, G. Birgegard, and P. Nasman Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study Leukemia 21 2007 627 632
13. D.H. Henry The role of intravenous iron in cancer-related anemia Oncology (Williston Park) 20 2006 21 24
14. D.H. Henry, N.V. Dahl, M. Auerbach, S. Tchekmedyian, and L.R. Laufman Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy Oncologist 12 2007 231 242
15. P. Pedrazzoli, A. Farris, and S. Del Prete Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha J Clin Oncol 26 2008 1619 1625
16. J. Bohlius, S. Langensiepen, and G. Schwarzer Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis J Natl Cancer Inst 97 2005 489 498
17. M. Henke, D. Mattern, and M. Pepe Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24 2006 4708 4713
18. J. Bohlius, K. Schmidlin, and C. Brillant Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Lancet 373 2009 1532 1542
19. J.D. Rizzo, M. Brouwers, and P. Hurley American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer J Clin Oncol 28 2010 4996 5010
20. European Medicines Agency. EMEA recommends a new warning for epoetins for their use in cancer patients. London, 26 June 2008 (EMEA/CHMP/333963/2008). Available from: < http://www.ema.europa.eu/docs/en-GB/document-library/Press- release/2009/11/WC500015069.pdf >.
21. E. Guardiola, F. Morschhauser, J.J. Zambrowski, and E.C. Antoine Management of anaemia in patient with cancer: results of the F-ACT study (French Anaemia Cancer Treatment) Bull Cancer 94 2007 907 914
22. Schneider M. Fréquence de l'anémie chez les patients franais atteints de tumeurs solides ou d'hémopathies malignes: résultats de l' European Cancer Anaemia Survey (ECAS). Oncologie 2005;7:397-702.
23. J.D. Rizzo, M.R. Somerfield, and K.L. Hagerty Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update J Clin Oncol 26 2008 132 149
24. C. Bokemeyer, M.S. Aapro, and A. Courdi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update Eur J Cancer 43 2007 258 270
25. Cancer- and Chemotherapy-induced anemia. NCCN Clinical Practice Guidelines in Oncology. Version 2.2011.
26. E. Luporsi, L. Mahi, C. Moore, J. Wernli, and R. Bugat Cost savings with ferric carboxymaltose through its impact on erythropoiesis-stimulating agents and blood transfusion in chemotherapy-induced anemia of breast and gastrointestinal cancer: French health care payer perspective Value Health 14 2011 A159 A160
27. H.J. Alter, and H.G. Klein The hazards of blood transfusion in historical perspective Blood 112 2008 2617 2626